Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928845 | 0.93 | MAPT (0.45) | MAPTTAAR1LMNASMN1; SMN2TGM2 | |
| SCHEMBL926558 | 0.91 | MAPT (0.54) | MAPTLMNASMN1; SMN2NAMPTALDH1A1 | |
| SCHEMBL926201 | 0.91 | MAPT (0.44) | MAPTTAAR1LMNASMN1; SMN2RORC | |
| SCHEMBL926737 | 0.89 | LMNA (0.46) | MAPTLMNASMN1; SMN2RORCALDH1A1 | |
| SCHEMBL926976 | 0.88 | HSD11B1 (0.46) | MAPTTAAR1LMNASMN1; SMN2KMT2A | |
| SCHEMBL926180 | 0.88 | LMNA (0.48) | MAPTLMNASMN1; SMN2TDP1HPGD | |
| SCHEMBL927527 | 0.86 | FKBP1A (0.48) | LMNASMN1; SMN2TGM2RAB9AKMT2A | |
| SCHEMBL926338 | 0.86 | FKBP1A (0.49) | RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL926834 | 0.84 | RORC (0.50) | SMN1; SMN2TGM2RORCALDH1A1 | |
| SCHEMBL926686 | 0.83 | ESRRG (0.47) | TGM2RAB9AKMT2AMEN1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872021-B2 | LXR receptor modulators | LABORATORIES FOURNIER S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | MAPT 1687/4885TAAR1 742/4885LMNA 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.